{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:18:35Z","timestamp":1792268315550,"version":"4.4.0"},"reference-count":180,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/SKK08\/IMU\/02\/2"],"award-info":[{"award-number":["FRGS\/1\/2018\/SKK08\/IMU\/02\/2"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>The blood-brain barrier (BBB) plays a crucial role in the central nervous system by tightly\nregulating the influx and efflux of biological substances between the brain parenchyma and peripheral\ncirculation. Its restrictive nature acts as an obstacle to protect the brain from potentially noxious substances\nsuch as blood-borne toxins, immune cells, and pathogens. Thus, the maintenance of its structural\nand functional integrity is vital in the preservation of neuronal function and cellular homeostasis\nin the brain microenvironment. However, the barrier\u2019s foundation can become compromised during\nneurological or pathological conditions, which can result in dysregulated ionic homeostasis, impaired\ntransport of nutrients, and accumulation of neurotoxins that eventually lead to irreversible neuronal\nloss. Initially, the BBB is thought to remain intact during neurodegenerative diseases, but accumulating\nevidence as of late has suggested the possible association of BBB dysfunction with Parkinson\u2019s\ndisease (PD) pathology. The neurodegeneration occurring in PD is believed to stem from a myriad of\npathogenic mechanisms, including tight junction alterations, abnormal angiogenesis, and dysfunctional\nBBB transporter mechanism, which ultimately causes altered BBB permeability. In this review, the\nmajor elements of the neurovascular unit (NVU) comprising the BBB are discussed, along with their\nrole in the maintenance of barrier integrity and PD pathogenesis. We also elaborated on how the neuroendocrine\nsystem can influence the regulation of BBB function and PD pathogenesis. Several novel\ntherapeutic approaches targeting the NVU components are explored to provide a fresh outlook on\ntreatment options for PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871527322666230330093829","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T23:58:30Z","timestamp":1680220710000},"page":"315-330","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel\nTherapeutic Approaches"],"prefix":"10.2174","volume":"23","author":[{"given":"Sarah Lei Qi","family":"Khor","sequence":"first","affiliation":[{"name":"School of Health Science, International Medical University, 57000, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuen Yen","family":"Ng","sequence":"additional","affiliation":[{"name":"School of Pharmacy,\nMonash University, 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhun Yian","family":"Koh","sequence":"additional","affiliation":[{"name":"Division of Applied Biomedical Science and Biotechnology, School of\nHealth Science, International Medical University, 57000, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soi Moi","family":"Chye","sequence":"additional","affiliation":[{"name":"Division of Applied Biomedical Science and Biotechnology, School of\nHealth Science, International Medical University, 57000, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Parkinson disease. Nat Rev Dis Primers 2017,3(1),17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3727\/000000007783464731","volume":"16","author":"Desai B.S.","year":"2007","unstructured":"Desai B.S.; Monahan A.J.; Carvey P.M.; Hendey B.; Blood-brain barrier pathology in Alzheimer\u2019s and Parkinson\u2019s disease: Implications for drug therapy. Cell Transplant 2007,16(3),285-299","journal-title":"Cell Transplant"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"611761","DOI":"10.3389\/fimmu.2021.611761","volume":"12","author":"Bogale T.A.","year":"2021","unstructured":"Bogale T.A.; Faustini G.; Longhena F.; Mitola S.; Pizzi M.; Bellucci A.; Alpha-synuclein in the regulation of brain endothelial and perivascular cells: Gaps and future perspectives. Front Immunol 2021,12(2),611761","journal-title":"Front Immunol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/mds.21065","volume":"21","author":"Braak H.","year":"2006","unstructured":"Braak H.; Bohl J.R.; M\u00fcller C.M.; R\u00fcb U.; de Vos R.A.I.; Del Tredici K.; Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson\u2019s disease reconsidered. Mov Disord 2006,21(12),2042-2051","journal-title":"Mov Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fneur.2018.00455","volume":"9","author":"Gigu\u00e8re N.","year":"2018","unstructured":"Gigu\u00e8re N.; Burke Nanni S.; Trudeau L.E.; On cell loss and selective vulnerability of neuronal populations in Parkinson\u2019s disease. Front Neurol 2018,9,455","journal-title":"Front Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"Seppi K.","year":"2019","unstructured":"Seppi K.; Ray Chaudhuri K.; Coelho M.; the collaborators of the Parkinson\u2019s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence\u2010based medicine review. Mov Disord 2019,34(2),180-198","journal-title":"Mov Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gendis.2019.01.004","volume":"6","author":"Selvaraj S.","year":"2019","unstructured":"Selvaraj S.; Piramanayagam S.; Impact of gene mutation in the development of Parkinson\u2019s disease. Genes Dis 2019,6(2),120-128","journal-title":"Genes Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"Jankovic J.","year":"2020","unstructured":"Jankovic J.; Tan E.K.; Parkinson\u2019s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020,91(8),795-808","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","volume":"57","author":"Zlokovic B.V.","year":"2008","unstructured":"Zlokovic B.V.; The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008,57(2),178-201","journal-title":"Neuron"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41574-019-0213-7","volume":"15","author":"Banks W.A.","year":"2019","unstructured":"Banks W.A.; The blood\u2013brain barrier as an endocrine tissue. Nat Rev Endocrinol 2019,15(8),444-455","journal-title":"Nat Rev Endocrinol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.23648","volume":"72","author":"Daneman R.","year":"2012","unstructured":"Daneman R.; The blood-brain barrier in health and disease. Ann Neurol 2012,72(5),648-672","journal-title":"Ann Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2741\/4206","volume":"19","author":"Lee H.","year":"2014","unstructured":"Lee H.; Pienaar I.S.; Disruption of the blood-brain barrier in parkinson\u2019s disease: Curse or route to a cure. Front Biosci 2014,19(2),272-280","journal-title":"Front Biosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1017\/S1462399411001918","volume":"13","author":"Grammas P.","year":"2011","unstructured":"Grammas P.; Martinez J.; Miller B.; Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011,13,e19","journal-title":"Expert Rev Mol Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0271678X16679420","volume":"37","year":"2017","unstructured":"Erd\u0151 F, Denes L, de Lange E. Age-associated physiological and pathological changes at the blood\u2013brain barrier: A review. J Cereb Blood Flow Metab 2017,37(1),4-24","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ana.410010502","volume":"1","author":"Oldendorf W.H.","year":"1977","unstructured":"Oldendorf W.H.; Cornford M.E.; Brown W.J.; The large apparent work capability of the blood-brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1977,1(5),409-417","journal-title":"Ann Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1113\/jphysiol.1990.sp018243","volume":"429","author":"Butt A.M.","year":"1990","unstructured":"Butt A.M.; Jones H.C.; Abbott N.J.; Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study. J Physiol 1990,429(1),47-62","journal-title":"J Physiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0005-2736(93)90083-C","volume":"1150","author":"Jett\u00e9 L.","year":"1993","unstructured":"Jett\u00e9 L.; T\u00eatu B.; B\u00e9liveau R.; High levels of P-glycoprotein detected in isolated brain capillaries. Biochim Biophys Acta Biomembr 1993,1150(2),147-154","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/nn.2946","volume":"14","author":"Winkler E.A.","year":"2011","unstructured":"Winkler E.A.; Bell R.D.; Zlokovic B.V.; Central nervous system pericytes in health and disease. Nat Neurosci 2011,14(11),1398-1405","journal-title":"Nat Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature09522","volume":"468","author":"Armulik A.","year":"2010","unstructured":"Armulik A.; Genov\u00e9 G.; M\u00e4e M.; Pericytes regulate the blood\u2013brain barrier. Nature 2010,468(7323),557-561","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fncel.2014.00211","volume":"8","author":"Cabezas R.","year":"2014","unstructured":"Cabezas R.; \u00c1vila M.; Gonzalez J.; Astrocytic modulation of blood brain barrier: Perspectives on Parkinson\u2019s disease. Front Cell Neurosci 2014,8(8),211","journal-title":"Front Cell Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1387\/ijdb.103167dr","volume":"55","author":"Ribatti D.","year":"2011","unstructured":"Ribatti D.; Nico B.; Crivellato E.; The role of pericytes in angiogenesis. Int J Dev Biol 2011,55(3),261-268","journal-title":"Int J Dev Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e35577","DOI":"10.1371\/journal.pone.0035577","volume":"7","author":"Paul G.","year":"2012","unstructured":"Paul G.; \u00d6zen I.; Christophersen N.S.; The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS ONE 2012,7(4),e35577","journal-title":"PLoS ONE"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fnins.2017.00224","volume":"11","author":"Haddad-T\u00f3volli R.","year":"2017","unstructured":"Haddad-T\u00f3volli R.; Dragano N.R.V.; Ramalho A.F.S.; Velloso L.A.; Development and function of the blood-brain barrier in the context of metabolic control. Front Neurosci 2017,11,224","journal-title":"Front Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuroscience.2015.01.007","volume":"323","author":"Rodr\u00edguez-Arellano J.J.","year":"2016","unstructured":"Rodr\u00edguez-Arellano J.J.; Parpura V.; Zorec R.; Verkhratsky A.; Astrocytes in physiological aging and Alzheimer\u2019s disease. Neuroscience 2016,323,170-182","journal-title":"Neuroscience"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1242\/dev.077214","volume":"139","author":"Tien A.C.","year":"2012","unstructured":"Tien A.C.; Tsai H.H.; Molofsky A.V.; Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development 2012,139(14),2477-2487","journal-title":"Development"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2009-12-257832","volume":"116","author":"Fantin A.","year":"2010","unstructured":"Fantin A.; Vieira J.M.; Gestri G.; Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010,116(5),829-840","journal-title":"Blood"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1038\/s41467-019-13812-z","volume":"10","author":"Haruwaka K.","year":"2019","unstructured":"Haruwaka K.; Ikegami A.; Tachibana Y.; Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun 2019,10(1),5816","journal-title":"Nat Commun"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.nbd.2009.05.018","volume":"35","author":"Astradsson A.","year":"2009","unstructured":"Astradsson A.; Jenkins B.G.; Choi J.K.; The blood\u2013brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates-Evidence from in vivo neuroimaging studies. Neurobiol Dis 2009,35(3),348-351","journal-title":"Neurobiol Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.20369","volume":"57","author":"Kortekaas R.","year":"2005","unstructured":"Kortekaas R.; Leenders K.L.; van Oostrom J.C.H.; Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005,57(2),176-179","journal-title":"Ann Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"Winner B.","year":"2011","unstructured":"Winner B.; Jappelli R.; Maji S.K.; In vivo demonstration that \u03b1-synuclein oligomers are toxic. Proc Natl Acad Sci 2011,108(10),4194-4199","journal-title":"Proc Natl Acad Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","volume":"37","author":"Sharon R.","year":"2003","unstructured":"Sharon R.; Bar-Joseph I.; Frosch M.P.; Walsh D.M.; Hamilton J.A.; Selkoe D.J.; The formation of highly soluble oligomers of \u03b1-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease. Neuron 2003,37(4),583-595","journal-title":"Neuron"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/brain\/awn349","volume":"132","author":"Paleologou K.E.","year":"2009","unstructured":"Paleologou K.E.; Kragh C.L.; Mann D.M.A.; Detection of elevated levels of soluble \u03b1-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009,132(Pt 4),1093-1101","journal-title":"Brain"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neulet.2013.06.058","volume":"551","author":"Jangula A.","year":"2013","unstructured":"Jangula A.; Murphy E.J.; Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expression. Neurosci Lett 2013,551,23-27","journal-title":"Neurosci Lett"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.peptides.2014.09.018","volume":"62","author":"Sui Y.T.","year":"2014","unstructured":"Sui Y.T.; Bullock K.M.; Erickson M.A.; Zhang J.; Banks W.A.; Alpha synuclein is transported into and out of the brain by the blood\u2013brain barrier. Peptides 2014,62,197-202","journal-title":"Peptides"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5012129","volume":"2017","author":"Longhena F.","year":"2017","unstructured":"Longhena F.; Faustini G.; Missale C.; Pizzi M.; Spano P.; Bellucci A.; The contribution of \u03b1-synuclein spreading to Parkinson\u2019s disease synaptopathy. Neural Plast 2017,2017,1-15","journal-title":"Neural Plast"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"Devi L.","year":"2008","unstructured":"Devi L.; Raghavendran V.; Prabhu B.M.; Avadhani N.G.; Anandatheerthavarada H.K.; Mitochondrial import and accumulation of \u03b1-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008,283(14),9089-9100","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0891-5849(99)00112-4","volume":"27","author":"Lagrange P.","year":"1999","unstructured":"Lagrange P.; Romero I.A.; Minn A.; Revest P.A.; Transendothelial permeability changes induced by free radicals in an in vitromodel of the blood-brain barrier. Free Radic Biol Med 1999,27(5-6),667-672","journal-title":"Free Radic Biol Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0026-2862(02)00009-2","volume":"65","author":"Gaillard P.","year":"2003","unstructured":"Gaillard P.; de Boer A.B.; Breimer D.D.; Pharmacological investigations on lipopolysaccharide-induced permeability changes in the blood-brain barrier in vitro. Microvasc Res 2003,65(1),24-31","journal-title":"Microvasc Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.1523\/JNEUROSCI.23-25-08733.2003","volume":"23","author":"Kim G.W.","year":"2003","unstructured":"Kim G.W.; Gasche Y.; Grzeschik S.; Copin J.C.; Maier C.M.; Chan P.H.; Neurodegeneration in striatum induced by the mitochondrial toxin 3-nitropropionic acid: Role of matrix metalloproteinase-9 in early blood-brain barrier disruption. J Neurosci 2003,23(25),8733-8742","journal-title":"J Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00401-003-0766-2","volume":"106","author":"Imamura K.","year":"2003","unstructured":"Imamura K.; Hishikawa N.; Sawada M.; Nagatsu T.; Yoshida M.; Hashizume Y.; Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol 2003,106(6),518-526","journal-title":"Acta Neuropathol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0304-3940(96)12706-3","volume":"211","author":"Mogi M.","year":"1996","unstructured":"Mogi M.; Harada M.; Narabayashi H.; Inagaki H.; Minami M.; Nagatsu T.; Interleukin (IL)-1\u03b2 IL-2, IL-4, IL-6 and transforming growth factor-\u03b1 levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson\u2019s disease. Neurosci Lett 1996,211(1),13-16","journal-title":"Neurosci Lett"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"Pajares M.","year":"2020","unstructured":"Pajares M.; I Rojo A, Manda G, Bosc\u00e1 L, Cuadrado A. Inflammation in Parkinson\u2019s disease: Mechanisms and therapeutic implications. Cells 2020,9(7),1687","journal-title":"Cells"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.neurobiolaging.2007.04.006","volume":"29","author":"Su X.","year":"2008","unstructured":"Su X.; Maguire-Zeiss K.A.; Giuliano R.; Prifti L.; Venkatesh K.; Federoff H.J.; Synuclein activates microglia in a model of Parkinson\u2019s disease. Neurobiol Aging 2008,29(11),1690-1701","journal-title":"Neurobiol Aging"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"Zhang W.","year":"2005","unstructured":"Zhang W.; Wang T.; Pei Z.; Aggregated \u03b1\u2010synuclein activates microglia: A process leading to disease progression in Parkinson\u2019s disease. FASEB J 2005,19(6),533-542","journal-title":"FASEB J"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/brain\/123.4.698","volume":"123","author":"Harkness K.A.","year":"2000","unstructured":"Harkness K.A.; Adamson P.; Sussman J.D.; Davies-Jones G.A.; Greenwood J.; Woodroofe M.N.; Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000,123(4),698-709","journal-title":"Brain"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jneuroim.2006.06.019","volume":"179","author":"Silwedel C.","year":"2006","unstructured":"Silwedel C.; F\u00f6rster C.; Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli. J Neuroimmunol 2006,179(1-2),37-45","journal-title":"J Neuroimmunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.expneurol.2004.08.008","volume":"190","author":"Wong D.","year":"2004","unstructured":"Wong D.; Dorovini-Zis K.; Vincent S.R.; Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol 2004,190(2),446-455","journal-title":"Exp Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/mol.105.017954","volume":"69","author":"Hartz A.M.S.","year":"2006","unstructured":"Hartz A.M.S.; Bauer B.; Fricker G.; Miller D.S.; Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-\u03b1 and lipopolysaccharide. Mol Pharmacol 2006,69(2),462-470","journal-title":"Mol Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.2174\/138161211797440122","volume":"17","author":"Bartels A.L.","year":"2011","unstructured":"Bartels A.L.; Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des 2011,17(26),2771-2777","journal-title":"Curr Pharm Des"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","volume":"77","author":"Schinkel A.H.","year":"1994","unstructured":"Schinkel A.H.; Smit J.J.M.; van Tellingen O.; Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994,77(4),491-502","journal-title":"Cell"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00702-011-0684-8","volume":"119","author":"Desai Bradaric B.","year":"2012","unstructured":"Desai Bradaric B.; Patel A.; Schneider J.A.; Carvey P.M.; Hendey B.; Evidence for angiogenesis in Parkinson\u2019s disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm 2012,119(1),59-71","journal-title":"J Neural Transm"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(99)00641-8","volume":"353","author":"Faucheux B.A.","year":"1999","unstructured":"Faucheux B.A.; Agid Y.; Hirsch E.C.; Bonnet A-M.; Blood vessels change in the mesencephalon of patients with Parkinson\u2019s disease. Lancet 1999,353(9157),981-982","journal-title":"Lancet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00702-004-0256-2","volume":"112","author":"Barcia C.","year":"2005","unstructured":"Barcia C.; Bautista V.; S\u00e1nchez-Bahillo \u00c1.; Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 2005,112(9),1237-1248","journal-title":"J Neural Transm"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/j.1471-4159.2007.04567.x","volume":"101","author":"Rite I.","year":"2007","unstructured":"Rite I.; Machado A.; Cano J.; Venero J.L.; Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007,101(6),1567-1582","journal-title":"J Neurochem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.pharmthera.2010.12.004","volume":"130","author":"VanGilder R.L.","year":"2011","unstructured":"VanGilder R.L.; Rosen C.L.; Barr T.L.; Huber J.D.; Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther 2011,130(3),239-247","journal-title":"Pharmacol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2012.07.010","volume":"322","author":"Baloyannis S.J.","year":"2012","unstructured":"Baloyannis S.J.; Baloyannis I.S.; The vascular factor in Alzheimer\u2019s disease: A study in Golgi technique and electron microscopy. J Neurol Sci 2012,322(1-2),117-121","journal-title":"J Neurol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s004010000195","volume":"100","author":"Farkas E.","year":"2000","unstructured":"Farkas E.; De Jong G.I.; de Vos R.A.I.; Jansen Steur E.N.H.; Luiten P.G.M.; Pathological features of cerebral cortical capillaries are doubled in Alzheimer\u2019s disease and Parkinson\u2019s disease. Acta Neuropathol 2000,100(4),395-402","journal-title":"Acta Neuropathol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"42984","DOI":"10.1038\/srep42984","volume":"7","author":"Dieriks BV","year":"2017","unstructured":"Dieriks BV; Park TIH; Fourie C; Faull RLM; Dragunow M; Curtis MA;  \u03b1-synuclein transfer through tunneling nanotubes occurs in\tSH-SY5Y cells and primary brain pericytes from Parkinson\u2019s disease\tpatients. Sci Rep 2017,7(1),42984","journal-title":"Sci Rep"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mvr.2019.03.005","volume":"124","author":"Dohgu S.","year":"2019","unstructured":"Dohgu S.; Takata F.; Matsumoto J.; Kimura I.; Yamauchi A.; Kataoka Y.; Monomeric \u03b1-synuclein induces blood\u2013brain barrier dysfunction through activated brain pericytes releasing inflammatory mediators in vitro. Microvasc Res 2019,124,61-66","journal-title":"Microvasc Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41598-020-80889-8","volume":"11","author":"Elabi O.","year":"2021","unstructured":"Elabi O.; Gaceb A.; Carlsson R.; Human \u03b1-synuclein overexpression in a mouse model of Parkinson\u2019s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation. Sci Rep 2021,11(1),1120","journal-title":"Sci Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/jcbfm.2015.32","volume":"35","author":"Gray M.T.","year":"2015","unstructured":"Gray M.T.; Woulfe J.M.; Striatal blood-brain barrier permeability in Parkinson\u2019s disease. J Cereb Blood Flow Metab 2015,35(5),747-750","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0271678X17719645","volume":"38","author":"Gaceb A.","year":"2018","unstructured":"Gaceb A.; \u00d6zen I.; Padel T.; Barbariga M.; Paul G.; Pericytes secrete pro-regenerative molecules in response to platelet-derived growth factor-BB. J Cereb Blood Flow Metab 2018,38(1),45-57","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/glia.22575","volume":"61","author":"Alvarez J.I.","year":"2013","unstructured":"Alvarez J.I.; Katayama T.; Prat A.; Glial influence on the blood brain barrier. Glia 2013,61(12),1939-1958","journal-title":"Glia"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/antiox8080265","volume":"8","author":"Rizor A.","year":"2019","unstructured":"Rizor A.; Pajarillo E.; Johnson J.; Aschner M.; Lee E.; Astrocytic oxidative\/nitrosative stress contributes to Parkinson\u2019s disease pathogenesis: The dual role of reactive astrocytes. Antioxidants 2019,8(8),265","journal-title":"Antioxidants"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1523\/JNEUROSCI.6221-11.2012","volume":"32","author":"Zamanian J.L.","year":"2012","unstructured":"Zamanian J.L.; Xu L.; Foo L.C.; Genomic analysis of reactive astrogliosis. J Neurosci 2012,32(18),6391-6410","journal-title":"J Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"Liddelow S.A.","year":"2017","unstructured":"Liddelow S.A.; Guttenplan K.A.; Clarke L.E.; Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017,541(7638),481-487","journal-title":"Nature"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1046\/j.1471-4159.1999.0732469.x","volume":"73","year":"1999","unstructured":"MCNaught KSP Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic\/ventral mesencephalic co-cultures. J Neurochem 1999,73(6),2469-2476","journal-title":"J Neurochem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1006\/nbdi.2000.0289","volume":"7","author":"Herrera A.J.","year":"2000","unstructured":"Herrera A.J.; Casta\u00f1o A.; Venero J.L.; Cano J.; Machado A.; The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000,7(4),429-447","journal-title":"Neurobiol Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1523\/JNEUROSCI.19-09-03440.1999","volume":"19","author":"Hunot S.","year":"1999","unstructured":"Hunot S.; Dugas N.; Faucheux B.; FcepsilonRII\/CD23 is expressed in Parkinson\u2019s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-\u03b1 in glial cells. J Neurosci 1999,19(9),3440-3447","journal-title":"J Neurosci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00019052-200108000-00009","volume":"14","author":"Vila M.","year":"2001","unstructured":"Vila M.; Jackson-Lewis V.; Gu\u00e9gan C.; The role of glial cells in Parkinson\u02bcs disease. Curr Opin Neurol 2001,14(4),483-489","journal-title":"Curr Opin Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","volume":"991","author":"Hirsch E.C.","year":"2003","unstructured":"Hirsch E.C.; Breidert T.; Rousselet E.; Hunot S.; Hartmann A.; Michel P.P.; The role of glial reaction and inflammation in Parkinson\u2019s disease. Ann N Y Acad Sci 2003,991(1),214-228","journal-title":"Ann N Y Acad Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2047-9158-2-20","volume":"2","author":"Braidy N.","year":"2013","unstructured":"Braidy N.; Gai W.P.; Xu Y.H.; Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl Neurodegener 2013,2(1),20","journal-title":"Transl Neurodegener"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nbd.2017.04.011","volume":"103","author":"Cavaliere F.","year":"2017","unstructured":"Cavaliere F.; Cerf L.; Dehay B.; In vitro \u03b1-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiol Dis 2017,103,101-112","journal-title":"Neurobiol Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neulet.2009.11.034","volume":"469","author":"Koob A.O.","year":"2010","unstructured":"Koob A.O.; Paulino A.D.; Masliah E.; GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with \u03b1-synuclein. Neurosci Lett 2010,469(1),11-14","journal-title":"Neurosci Lett"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mcn.2017.04.009","volume":"82","author":"Lindstr\u00f6m V.","year":"2017","unstructured":"Lindstr\u00f6m V.; Gustafsson G.; Sanders L.H.; Extensive uptake of \u03b1-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol Cell Neurosci 2017,82,143-156","journal-title":"Mol Cell Neurosci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"11835","DOI":"10.1523\/JNEUROSCI.0983-17.2017","volume":"37","author":"Rostami J.","year":"2017","unstructured":"Rostami J.; Holmqvist S.; Lindstr\u00f6m V.; Human astrocytes transfer aggregated alpha-synuclein viatunneling nanotubes. J Neurosci 2017,37(49),11835-11853","journal-title":"J Neurosci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-6606-3-12","volume":"3","author":"Gu X.L.","year":"2010","unstructured":"Gu X.L.; Long C.X.; Sun L.; Xie C.; Lin X.; Cai H.; Astrocytic expression of Parkinson\u2019s disease-related A53T \u03b1-synuclein causes neurodegeneration in mice. Mol Brain 2010,3(1),12","journal-title":"Mol Brain"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/glia.24109","volume":"70","author":"Lan G.","year":"2022","unstructured":"Lan G.; Wang P.; Chan R.B.; Astrocytic VEGFA: An essential mediator in blood\u2013brain\u2010barrier disruption in Parkinson\u2019s disease. Glia 2022,70(2),337-353","journal-title":"Glia"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11481-012-9401-0","volume":"8","author":"B\u00e9raud D.","year":"2013","unstructured":"B\u00e9raud D.; Hathaway H.A.; Trecki J.; Microglial activation and antioxidant responses induced by the Parkinson\u2019s disease protein \u03b1-synuclein. J Neuroimmune Pharmacol 2013,8(1),94-117","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/ijms23052793","volume":"23","author":"Ruan Z.","year":"2022","unstructured":"Ruan Z.; Zhang D.; Huang R.; Microglial activation damages dopaminergic neurons through MMP-2\/-9-mediated increase of blood-brain barrier permeability in a Parkinson\u2019s disease mouse model. Int J Mol Sci 2022,23(5),2793","journal-title":"Int J Mol Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e110024","DOI":"10.1371\/journal.pone.0110024","volume":"9","author":"Wang Y.","year":"2014","unstructured":"Wang Y.; Jin S.; Sonobe Y.; Cheng Y.; Horiuchi H.; Parajuli B.; Interleukin-1\u03b2 induces blood-brain barrier disruption by downregulating sonic hedgehog in astrocytes. PLoS One 2014,9(10),e110024","journal-title":"PLoS One"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4049\/jimmunol.1200409","volume":"189","author":"Allen C.","year":"2012","unstructured":"Allen C.; Thornton P.; Denes A.; Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol 2012,189(1),381-392","journal-title":"J Immunol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10571-009-9446-7","volume":"30","author":"Sumi N.","year":"2010","unstructured":"Sumi N.; Nishioku T.; Takata F.; Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. Cell Mol Neurobiol 2010,30(2),247-253","journal-title":"Cell Mol Neurobiol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ajpath.2011.04.013","volume":"179","author":"Stefanova N.","year":"2011","unstructured":"Stefanova N.; Fellner L.; Reindl M.; Masliah E.; Poewe W.; Wenning G.K.; Toll-like receptor 4 promotes \u03b1-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol 2011,179(2),954-963","journal-title":"Am J Pathol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2045-8118-8-8","volume":"8","author":"Bonkowski D.","year":"2011","unstructured":"Bonkowski D.; Katyshev V.; Balabanov R.D.; Borisov A.; Dore-Duffy P.; The CNS microvascular pericyte: Pericyte-astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS 2011,8(1),8","journal-title":"Fluids Barriers CNS"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jnr.21884","volume":"87","author":"Kim J.H.","year":"2009","unstructured":"Kim J.H.; Kim J.H.; Yu Y.S.; Kim D.H.; Kim K.W.; Recruitment of pericytes and astrocytes is closely related to the formation of tight junction in developing retinal vessels. J Neurosci Res 2009,87(3),653-659","journal-title":"J Neurosci Res"},{"key":"ref=87","first-page":"3049","volume":"18","author":"M\u00e1ndi Y.","year":"1998","unstructured":"M\u00e1ndi Y.; Ocsovszki I.; Szabo D.; Nagy Z.; Nelson J.; Molnar J.; Nitric oxide production and MDR expression by human brain endothelial cells. Anticancer Res 1998,18(4C),3049-3052","journal-title":"Anticancer Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbi.2005.10.005","volume":"20","author":"Verma S.","year":"2006","unstructured":"Verma S.; Nakaoke R.; Dohgu S.; Banks W.A.; Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun 2006,20(5),449-455","journal-title":"Brain Behav Immun"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0006-8993(99)02189-7","volume":"851","author":"Reyes T.M.","year":"1999","unstructured":"Reyes T.M.; Fabry Z.; Coe C.L.; Brain endothelial cell production of a neuroprotective cytokine, interleukin-6, in response to noxious stimuli. Brain Res 1999,851(1-2),215-220","journal-title":"Brain Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1016\/S0024-3205(03)00172-3","volume":"72","author":"McGuire T.R.","year":"2003","unstructured":"McGuire T.R.; Trickler W.J.; Hock L.; Vrana A.; Hoie E.B.; Miller D.W.; Release of prostaglandin E-2 in bovine brain endothelial cells after exposure to three unique forms of the antifungal drug amphotericin-B: Role of COX-2 in amphotericin-B induced fever. Life Sci 2003,72(23),2581-2590","journal-title":"Life Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2826.2002.00778.x","volume":"14","author":"Kis B.","year":"2002","unstructured":"Kis B.; Kaiya H.; Nishi R.; Cerebral endothelial cells are a major source of adrenomedullin. J Neuroendocrinol 2002,14(4),283-293","journal-title":"J Neuroendocrinol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1177\/0271678X17740793","volume":"38","author":"Banks W.A.","year":"2018","unstructured":"Banks W.A.; Kovac A.; Morofuji Y.; Neurovascular unit crosstalk: Pericytes and astrocytes modify cytokine secretion patterns of brain endothelial cells. J Cereb Blood Flow Metab 2018,38(6),1104-1118","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/WNL.0b013e318233b3e4","volume":"77","author":"Benarroch E.E.","year":"2011","unstructured":"Benarroch E.E.; Nitric oxide: A pleiotropic signal in the nervous system. Neurology 2011,77(16),1568-1576","journal-title":"Neurology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pharmthera.2005.05.007","volume":"109","author":"Zhang L.","year":"2006","unstructured":"Zhang L.; Dawson V.L.; Dawson T.M.; Role of nitric oxide in Parkinson\u2019s disease. Pharmacol Ther 2006,109(1-2),33-41","journal-title":"Pharmacol Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1002\/ana.410440716","volume":"44","author":"Beal M.F.","year":"1998","unstructured":"Beal M.F.; M. Flint Beal. Excitotoxicity and nitric oxide in parkinson\u2019s disease pathogenesis. Ann Neurol 1998,44(S1),S110-S114","journal-title":"Ann Neurol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1007\/s11064-008-9697-6","volume":"33","author":"Aquilano K.","year":"2008","unstructured":"Aquilano K.; Baldelli S.; Rotilio G.; Ciriolo M.R.; Role of nitric oxide synthases in Parkinson\u2019s disease: A review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 2008,33(12),2416-2426","journal-title":"Neurochem Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.1093891","volume":"304","author":"Chung K.K.K.","year":"2004","unstructured":"Chung K.K.K.; Thomas B.; Li X.; S-nitrosylation of parkin regulates ubiquitination and compromises parkin\u2019s protective function. Science 2004,304(5675),1328-1331","journal-title":"Science"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13311-017-0600-5","volume":"15","author":"Farzi A.","year":"2018","unstructured":"Farzi A.; Fr\u00f6hlich E.E.; Holzer P.; Gut microbiota and the neuroendocrine system. Neurotherapeutics 2018,15(1),5-22","journal-title":"Neurotherapeutics"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1073\/pnas.1010529108","volume":"108","author":"Heijtz R.D.","year":"2011","unstructured":"Heijtz R.D.; Wang S.; Anuar F.; Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci 2011,108(7),3047-3052","journal-title":"Proc Natl Acad Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"263ra158","DOI":"10.1126\/scitranslmed.3009759","volume":"6","author":"Braniste V.","year":"2014","unstructured":"Braniste V.; Al-Asmakh M.; Kowal C.; Anuar F.; Abbaspour A.; Toth M.; The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 2014,6(263),263ra158","journal-title":"Sci Transl Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14737175.2020.1701437","volume":"20","author":"Mulak A.","year":"2020","unstructured":"Mulak A.; An overview of the neuroendocrine system in Parkinson\u2019s disease: What is the impact on diagnosis and treatment. Expert Rev Neurother 2020,20(2),127-135","journal-title":"Expert Rev Neurother"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"Fasano A.","year":"2013","unstructured":"Fasano A.; Bove F.; Gabrielli M.; The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov Disord 2013,28(9),1241-1249","journal-title":"Mov Disord"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"Sampson T.R.","year":"2016","unstructured":"Sampson T.R.; Debelius J.W.; Thron T.; Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 2016,167(6),1469-1480.e12","journal-title":"Cell"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"Scheperjans F.","year":"2015","unstructured":"Scheperjans F.; Aho V.; Pereira P.A.B.; Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov Disord 2015,30(3),350-358","journal-title":"Mov Disord"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","volume":"50","author":"Devos D.","year":"2013","unstructured":"Devos D.; Lebouvier T.; Lardeux B.; Colonic inflammation in Parkinson\u2019s disease. Neurobiol Dis 2013,50,42-48","journal-title":"Neurobiol Dis"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/mds.25966","volume":"29","author":"Olanow C.W.","year":"2014","unstructured":"Olanow C.W.; Wakeman D.R.; Kordower J.H.; Peripheral alpha-synuclein and Parkinson\u2019s disease. Mov Disord 2014,29(8),963-966","journal-title":"Mov Disord"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yfrne.2017.09.002","volume":"50","author":"Jurado-Coronel J.C.","year":"2018","unstructured":"Jurado-Coronel J.C.; Cabezas R.; \u00c1vila Rodr\u00edguez M.F.; Echeverria V.; Garc\u00eda-Segura L.M.; Barreto G.E.; Sex differences in Parkinson\u2019s disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol 2018,50,18-30","journal-title":"Front Neuroendocrinol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1212\/WNL.55.9.1358","volume":"55","author":"Baldereschi M.","year":"2000","unstructured":"Baldereschi M.; Di Carlo A.; Rocca W.A.; ILSA Working Group Italian Longitudinal Study on Aging. Parkinson\u2019s disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. Neurology 2000,55(9),1358-1363","journal-title":"Neurology"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/jnnp.2006.103788","volume":"78","author":"Haaxma C.A.","year":"2007","unstructured":"Haaxma C.A.; Bloem B.R.; Borm G.F.; Gender differences in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2007,78(8),819-824","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/jnnp.2008.168211","volume":"80","author":"Alves G.","year":"2009","unstructured":"Alves G.; M\u00fcller B.; Herlofson K.; Norwegian ParkWest study group. Incidence of Parkinson\u2019s disease in Norway: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009,80(8),851-857","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.parkreldis.2013.07.020","volume":"19","author":"Cereda E.","year":"2013","unstructured":"Cereda E.; Barichella M.; Cassani E.; Caccialanza R.; Pezzoli G.; Reproductive factors and clinical features of Parkinson\u2019s disease. Parkinsonism Relat Disord 2013,19(12),1094-1099","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/mds.21127","volume":"21","author":"Ragonese P.","year":"2006","unstructured":"Ragonese P.; D\u2019Amelio M.; Callari G.; Salemi G.; Morgante L.; Savettieri G.; Age at menopause predicts age at onset of Parkinson\u2019s disease. Mov Disord 2006,21(12),2211-2214","journal-title":"Mov Disord"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/mds.1170","volume":"16","author":"Benedetti M.D.","year":"2001","unstructured":"Benedetti M.D.; Maraganore D.M.; Bower J.H.; Hysterectomy, menopause, and estrogen use preceding Parkinson\u2019s disease: An exploratory case-control study. Mov Disord 2001,16(5),830-837","journal-title":"Mov Disord"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.1038\/s41598-019-47026-6","volume":"9","author":"Lee Y.H.","year":"2019","unstructured":"Lee Y.H.; Cha J.; Chung S.J.; Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-na\u00efve postmenopausal Parkinson\u2019s disease. Sci Rep 2019,9(1),10531","journal-title":"Sci Rep"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.3390\/ijms20246251","volume":"20","author":"Chen Y.H.","year":"2019","unstructured":"Chen Y.H.; Wang V.; Huang E.Y.K.; Delayed dopamine dysfunction and motor deficits in female Parkinson model mice. Int J Mol Sci 2019,20(24),6251","journal-title":"Int J Mol Sci"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"011509","DOI":"10.1063\/5.0035610","volume":"5","author":"Weber C.M.","year":"2021","unstructured":"Weber C.M.; Clyne A.M.; Sex differences in the blood\u2013brain barrier and neurodegenerative diseases. APL Bioeng 2021,5(1),011509","journal-title":"APL Bioeng"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.yfrne.2008.04.001","volume":"29","author":"Vegeto E.","year":"2008","unstructured":"Vegeto E.; Benedusi V.; Maggi A.; Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 2008,29(4),507-519","journal-title":"Front Neuroendocrinol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.clim.2004.05.011","volume":"113","author":"Lang T.J.","year":"2004","unstructured":"Lang T.J.; Estrogen as an immunomodulator. Clin Immunol 2004,113(3),224-230","journal-title":"Clin Immunol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fimmu.2019.00938","volume":"10","author":"Purvis G.S.D.","year":"2019","unstructured":"Purvis G.S.D.; Solito E.; Thiemermann C.; Annexin-A1: Therapeutic potential in microvascular disease. Front Immunol 2019,10,938","journal-title":"Front Immunol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bbi.2015.08.020","volume":"51","author":"Maggioli E.","year":"2016","unstructured":"Maggioli E.; McArthur S.; Mauro C.; Estrogen protects the blood\u2013brain barrier from inflammation-induced disruption and increased lymphocyte trafficking. Brain Behav Immun 2016,51,212-222","journal-title":"Brain Behav Immun"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-015-1417-0","volume":"129","author":"Haarmann A.","year":"2015","unstructured":"Haarmann A.; Nowak E.; Dei\u00df A.; Soluble VCAM-1 impairs human brain endothelial barrier integrity viaintegrin \u03b1-4-transduced outside-in signalling. Acta Neuropathol 2015,129(5),639-652","journal-title":"Acta Neuropathol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12013-015-0522-y","volume":"72","author":"Hou X.","year":"2015","unstructured":"Hou X.; Pei F.; Estradiol inhibits cytokine-induced expression of VCAM-1 and ICAM-1 in cultured human endothelial cells via AMPK\/PPAR\u03b1 activation. Cell Biochem Biophys 2015,72(3),709-717","journal-title":"Cell Biochem Biophys"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.nbd.2013.06.004","volume":"58","author":"Rodriguez-Perez A.I.","year":"2013","unstructured":"Rodriguez-Perez A.I.; Dominguez-Meijide A.; Lanciego J.L.; Guerra M.J.; Labandeira-Garcia J.L.; Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson\u2019s disease. Neurobiol Dis 2013,58,209-219","journal-title":"Neurobiol Dis"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1242\/jcs.00755","volume":"116","author":"Stamatovic S.M.","year":"2003","unstructured":"Stamatovic S.M.; Keep R.F.; Kunkel S.L.; Andjelkovic A.V.; Potential role of MCP-1 in endothelial cell tight junction \u2018opening\u2019: Signaling via Rho and Rho kinase. J Cell Sci 2003,116(22),4615-4628","journal-title":"J Cell Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/01.RES.87.4.335","volume":"87","author":"Amerongen G.P.N.","year":"2000","unstructured":"Amerongen G.P.N.; Delft S.; Vermeer M.A.; Collard J.G.; van Hinsbergh V.W.M.; Activation of RhoA by thrombin in endothelial hyperpermeability: Role of Rho kinase and protein tyrosine kinases. Circ Res 2000,87(4),335-340","journal-title":"Circ Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/molecules23092371","volume":"23","author":"Feng S.","year":"2018","unstructured":"Feng S.; Zou L.; Wang H.; He R.; Liu K.; Zhu H.; RhoA\/ROCK-2 pathway inhibition and tight junction protein upregulation by catalpol suppresses lipopolysaccharide-induced disruption of blood-brain barrier permeability. Molecules 2018,23(9),2371","journal-title":"Molecules"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000438789","volume":"103","author":"Bourque M.","year":"2016","unstructured":"Bourque M.; Morissette M.; Al Sweidi S.; Caruso D.; Melcangi R.C.; Di Paolo T.; Neuroprotective effect of progesterone in MPTP-treated male mice. Neuroendocrinology 2016,103(3-4),300-314","journal-title":"Neuroendocrinology"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuropharm.2017.02.007","volume":"117","author":"Litim N.","year":"2017","unstructured":"Litim N.; Morissette M.; Di Paolo T.; Effects of progesterone administered after MPTP on dopaminergic neurons of male mice. Neuropharmacology 2017,117,209-218","journal-title":"Neuropharmacology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/mp.2017.167","volume":"23","author":"Alexaki V.I.","year":"2018","unstructured":"Alexaki V.I.; Fodelianaki G.; Neuwirth A.; DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1\/2-CREB-Jmjd3 pathway. Mol Psychiatry 2018,23(6),1410-1420","journal-title":"Mol Psychiatry"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"Fox S.H.","year":"2018","unstructured":"Fox S.H.; Katzenschlager R.; Lim S.Y.; Movement Disorder Society Evidence-Based Medicine Committee International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 2018,33(8),1248-1266","journal-title":"Mov Disord"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"Armstrong M.J.","year":"2020","unstructured":"Armstrong M.J.; Okun M.S.; Diagnosis and treatment of Parkinson disease: A review. JAMA 2020,323(6),548-560","journal-title":"JAMA"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0028-3886.226451","volume":"66","author":"Goyal V.","year":"2018","unstructured":"Goyal V.; Radhakrishnan D.M.; Parkinson\u2019s disease: A review. Neurol India 2018,66(7)(Suppl.),26","journal-title":"Neurol India"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"16005","DOI":"10.1038\/s41598-017-16228-1","volume":"7","author":"Lerner R.P.","year":"2017","unstructured":"Lerner R.P.; Francardo V.; Fujita K.; Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Sci Rep 2017,7(1),16005","journal-title":"Sci Rep"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","volume":"26","author":"Mercuri N.","year":"2005","unstructured":"Mercuri N.; Bernardi G.; The \u2018magic\u2019 of -dopa: why is it the gold standard Parkinson\u2019s disease therapy. Trends Pharmacol Sci 2005,26(7),341-344","journal-title":"Trends Pharmacol Sci"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.expneurol.2005.04.008","volume":"195","author":"Hawkins R.A.","year":"2005","unstructured":"Hawkins R.A.; Mokashi A.; Simpson I.A.; An active transport system in the blood\u2013brain barrier may reduce levodopa availability. Exp Neurol 2005,195(1),267-271","journal-title":"Exp Neurol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1471-4159.1994.62010045.x","volume":"62","author":"Makar T.K.","year":"1994","unstructured":"Makar T.K.; Nedergaard M.; Preuss A.; Gelbard A.S.; Perumal A.S.; Cooper A.J.L.; Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: Evidence that astrocytes play an important role in antioxidative processes in the brain. J Neurochem 1994,62(1),45-53","journal-title":"J Neurochem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/(SICI)1098-1136(20000101)29:1<25:AID-GLIA3>3.0.CO;2-G","volume":"29","author":"Lindenau J.","year":"2000","unstructured":"Lindenau J.; Noack H.; Possel H.; Asayama K.; Wolf G.; Cellular distribution of superoxide dismutases in the rat CNS. Glia 2000,29(1),25-34","journal-title":"Glia"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1046\/j.1471-4159.1996.66031227.x","volume":"66","author":"Siushansian R.","year":"1996","unstructured":"Siushansian R.; Dixon S.J.; Wilson J.X.; Osmotic swelling stimulates ascorbate efflux from cerebral astrocytes. J Neurochem 1996,66(3),1227-1233","journal-title":"J Neurochem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s11064-011-0471-9","volume":"36","author":"Mythri R.B.","year":"2011","unstructured":"Mythri R.B.; Venkateshappa C.; Harish G.; Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson\u2019s disease brains. Neurochem Res 2011,36(8),1452-1463","journal-title":"Neurochem Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"27230","DOI":"10.1074\/jbc.M212436200","volume":"278","author":"Norris E.H.","year":"2003","unstructured":"Norris E.H.; Giasson B.I.; Ischiropoulos H.; Lee V.M.Y.; Effects of oxidative and nitrative challenges on \u03b1-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 2003,278(29),27230-27240","journal-title":"J Biol Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","volume":"52","author":"Riederer P.","year":"1989","unstructured":"Riederer P.; Sofic E.; Rausch W.D.; Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989,52(2),515-520","journal-title":"J Neurochem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.neuro.2008.12.009","volume":"30","author":"Giordano G.","year":"2009","unstructured":"Giordano G.; Kavanagh T.J.; Costa L.G.; Mouse cerebellar astrocytes protect cerebellar granule neurons against toxicity of the Poly Brominated Diphenyl Ether (PBDE) mixture DE-71. Neurotoxicology 2009,30(2),326-329","journal-title":"Neurotoxicology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1023\/A:1021191729865","volume":"24","author":"Agarwal R.","year":"1999","unstructured":"Agarwal R.; Shukla G.S.; Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem Res 1999,24(12),1507-1514","journal-title":"Neurochem Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1210\/en.2011-1638","volume":"153","author":"Price T.O.","year":"2012","unstructured":"Price T.O.; Eranki V.; Banks W.A.; Ercal N.; Shah G.N.; Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 2012,153(1),362-372","journal-title":"Endocrinology"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","volume":"62","author":"Smeyne M.","year":"2013","unstructured":"Smeyne M.; Smeyne R.J.; Glutathione metabolism and Parkinson\u2019s disease. Free Radic Biol Med 2013,62,13-25","journal-title":"Free Radic Biol Med"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12906-019-2738-7","volume":"20","author":"Wang T.","year":"2020","unstructured":"Wang T.; Li C.; Han B.; Neuroprotective effects of Danshensu on rotenone-induced Parkinson\u2019s disease models in vitro and in vivo. BMC Complementary Medicine and Therapies 2020,20(1),20","journal-title":"BMC Complementary Medicine and Therapies"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"105878","DOI":"10.1016\/j.clineuro.2020.105878","volume":"195","author":"Daneshvar Kakhaki R.","year":"2020","unstructured":"Daneshvar Kakhaki R.; Ostadmohammadi V.; Kouchaki E.; Melatonin supplementation and the effects on clinical and metabolic status in Parkinson\u2019s disease: A randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg 2020,195,105878","journal-title":"Clin Neurol Neurosurg"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41467-020-14788-x","volume":"11","author":"Wei Y.","year":"2020","unstructured":"Wei Y.; Lu M.; Mei M.; Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection. Nat Commun 2020,11(1),941","journal-title":"Nat Commun"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/jcbfm.2009.277","volume":"30","author":"Lin J.L.","year":"2010","unstructured":"Lin J.L.; Huang Y.H.; Shen Y.C.; Huang H.C.; Liu P.H.; Ascorbic acid prevents blood-brain barrier disruption and sensory deficit caused by sustained compression of primary somatosensory cortex. J Cereb Blood Flow Metab 2010,30(6),1121-1136","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nbd.2007.11.013","volume":"30","author":"Botella J.A.","year":"2008","unstructured":"Botella J.A.; Bayersdorfer F.; Schneuwly S.; Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson\u2019s disease. Neurobiol Dis 2008,30(1),65-73","journal-title":"Neurobiol Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0306-4522(01)00237-8","volume":"105","author":"Kim G.W.","year":"2001","unstructured":"Kim G.W.; Lew\u00e9n A.; Copin J.C.; Watson B.D.; Chan P.H.; The cytosolic antioxidant, copper\/zinc superoxide dismutase, attenuates blood-brain barrier disruption and oxidative cellular injury after photothrombotic cortical ischemia in mice. Neuroscience 2001,105(4),1007-1018","journal-title":"Neuroscience"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nature13324","volume":"509","author":"Ben-Zvi A.","year":"2014","unstructured":"Ben-Zvi A.; Lacoste B.; Kur E.; Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 2014,509(7501),507-511","journal-title":"Nature"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.neuron.2017.02.043","volume":"93","author":"Chow B.W.","year":"2017","unstructured":"Chow B.W.; Gu C.; Gradual Suppression of transcytosis governs functional blood-retinal barrier formation. Neuron 2017,93(6),1325-1333","journal-title":"Neuron"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1326-5-32","volume":"5","author":"Winkler E.A.","year":"2010","unstructured":"Winkler E.A.; Bell R.D.; Zlokovic B.V.; Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener 2010,5(1),32","journal-title":"Mol Neurodegener"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1242\/dev.126.14.3047","volume":"126","author":"Hellstr\u00f6m M.","year":"1999","unstructured":"Hellstr\u00f6m M.; Kal n M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999,126(14),3047-3055","journal-title":"Development"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nm.2131","volume":"16","author":"Lebrin F.","year":"2010","unstructured":"Lebrin F.; Srun S.; Raymond K.; Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010,16(4),420-428","journal-title":"Nat Med"},{"key":"ref=157","author":"Lebrin F","year":"2015","unstructured":"Lebrin F; Soussain C; Thalgott J;  Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation 2015","journal-title":"Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnagi.2020.00031","volume":"12","author":"Casu M.A.","year":"2020","unstructured":"Casu M.A.; Mocci I.; Isola R.; Neuroprotection by the immunomodulatory drug pomalidomide in the Drosophila LRRK2WD40 genetic model of Parkinson\u2019s disease. Front Aging Neurosci 2020,12,31","journal-title":"Front Aging Neurosci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"e55375","DOI":"10.1371\/journal.pone.0055375","volume":"8","author":"Codolo G.","year":"2013","unstructured":"Codolo G.; Plotegher N.; Pozzobon T.; Brucale M.; Tessari I.; Bubacco L.; Triggering of inflammasome by aggregated \u03b1-synuclein, an inflammatory response in synucleinopathies. PLoS One 2013,8(1),e55375","journal-title":"PLoS One"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2005965","volume":"8","author":"Daniele S.G.","year":"2015","unstructured":"Daniele S.G.; B\u00e9raud D.; Davenport C.; Cheng K.; Yin H.; Maguire-Zeiss K.A.; Activation of MyD88-dependent TLR1\/2 signaling by misfolded \u03b1-synuclein, a protein linked to neurodegenerative disorders. Sci Signal 2015,8(376),ra45-ra5","journal-title":"Sci Signal"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1007\/s12035-015-9267-2","volume":"53","author":"Sharma N.","year":"2016","unstructured":"Sharma N.; Nehru B.; Apocyanin, a microglial NADPH oxidase inhibitor prevents dopaminergic neuronal degeneration in lipopolysaccharide-induced Parkinson\u2019s disease model. Mol Neurobiol 2016,53(5),3326-3337","journal-title":"Mol Neurobiol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/mol.110.064535","volume":"78","author":"Zhang F.","year":"2010","unstructured":"Zhang F.; Shi J.S.; Zhou H.; Wilson B.; Hong J.S.; Gao H.M.; Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010,78(3),466-477","journal-title":"Mol Pharmacol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1038\/cddis.2013.54","volume":"4","author":"Kobayashi K.","year":"2013","unstructured":"Kobayashi K.; Imagama S.; Ohgomori T.; Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 2013,4(3),e525-5","journal-title":"Cell Death Dis"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12974-015-0320-x","volume":"12","author":"Valera E.","year":"2015","unstructured":"Valera E.; Mante M.; Anderson S.; Rockenstein E.; Masliah E.; Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson\u2019s disease. J Neuroinflammat 2015,12(1),93","journal-title":"J Neuroinflammat"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fnagi.2017.00233","volume":"9","author":"Liu Z.","year":"2017","unstructured":"Liu Z.; Ran Y.; Huang S.; Curcumin protects against ischemic stroke by titrating microglia\/macrophage polarization. Front Aging Neurosci 2017,9,233","journal-title":"Front Aging Neurosci"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.intimp.2018.11.004","volume":"66","author":"Zhu Y.L.","year":"2019","unstructured":"Zhu Y.L.; Sun M.F.; Jia X.B.; Neuroprotective effects of Astilbin on MPTP-induced Parkinson\u2019s disease mice: Glial reaction, \u03b1-synuclein expression and oxidative stress. Int Immunopharmacol 2019,66,19-27","journal-title":"Int Immunopharmacol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","volume":"12","author":"McFarthing K.","year":"2022","unstructured":"McFarthing K.; Rafaloff G.; Baptista M.; Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2022 update. J Parkinsons Dis 2022,12(4),1073-1082","journal-title":"J Parkinsons Dis"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.3390\/cells11213468","volume":"11","author":"Hong C.T.","year":"2022","unstructured":"Hong C.T.; Chan L.; Chen K.Y.; Rifaximin modifies gut microbiota and attenuates inflammation in Parkinson\u2019s disease: Preclinical and clinical studies. Cells 2022,11(21),3468","journal-title":"Cells"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12974-015-0455-9","volume":"12","author":"Kim C.","year":"2015","unstructured":"Kim C.; Ojo-Amaize E.; Spencer B.; Hypoestoxide reduces neuroinflammation and \u03b1-synuclein accumulation in a mouse model of Parkinson\u2019s disease. J Neuroinflammation 2015,12(1),236","journal-title":"J Neuroinflammation"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","volume":"202","author":"Kim S.","year":"2009","unstructured":"Kim S.; Moon M.; Park S.; Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease. J Endocrinol 2009,202(3),431-439","journal-title":"J Endocrinol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"Athauda D.","year":"2017","unstructured":"Athauda D.; Maclagan K.; Skene S.S.; Exenatide once weekly versusplacebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial. Lancet 2017,390(10103),1664-1675","journal-title":"Lancet"},{"key":"ref=172","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.3068","volume":"98","author":"Malatt C.","year":"2022","unstructured":"Malatt C.; Wu T.; Bresee C.; Hogg E.; Wertheimer J.; Tan E.; Liraglutide improves non-motor function and activities of daily living in patients with Parkinson\u2019s disease: A randomized, double-blind, placebo-controlled trial (P9-11.005). Neurology 2022,98(18)(Suppl.) https:\/\/n.neurology.org\/content\/98\/18_Supplement\/3068","journal-title":"Neurology"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecam\/nep075","volume":"2011","author":"Zhang R.","year":"2011","unstructured":"Zhang R.; Xu S.; Cai Y.; Zhou M.; Zuo X.; Chan P.; Ganoderma lucidum protects dopaminergic neuron degeneration through inhibition of microglial activation. Evid Based Complement Alternat Med 2011,2011,1-9","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.apsb.2020.11.023","volume":"11","author":"Han L.","year":"2021","unstructured":"Han L.; Jiang C.; Evolution of blood\u2013brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. Acta Pharm Sin B 2021,11(8),2306-2325","journal-title":"Acta Pharm Sin B"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","volume":"4","author":"Singh A.P.","year":"2019","unstructured":"Singh A.P.; Biswas A.; Shukla A.; Maiti P.; Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther 2019,4(1),33","journal-title":"Signal Transduct Target Ther"},{"key":"ref=176","first-page":"376","volume":"14","author":"Gunay MS","year":"2016","unstructured":"Gunay MS; Ozer AY; Chalon S; Drug delivery systems for imaging\tand therapy of Parkinson\u2019s disease. CN  2016,14(4),376-91"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.3390\/molecules27092811","volume":"27","author":"Mogharbel B.F.","year":"2022","unstructured":"Mogharbel B.F.; Cardoso M.A.; Irioda A.C.; Biodegradable nanoparticles loaded with levodopa and curcumin for treatment of Parkinson\u2019s disease. Molecules 2022,27(9),2811","journal-title":"Molecules"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/mt.2011.164","volume":"19","author":"Zhuang X.","year":"2011","unstructured":"Zhuang X.; Xiang X.; Grizzle W.; Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011,19(10),1769-1779","journal-title":"Mol Ther"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/s41467-018-04529-6","volume":"9","author":"Lipsman N.","year":"2018","unstructured":"Lipsman N.; Meng Y.; Bethune A.J.; Blood-brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound. Nat Commun 2018,9(1),2336","journal-title":"Nat Commun"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acs.nanolett.7b00616","volume":"17","author":"Mead B.P.","year":"2017","unstructured":"Mead B.P.; Kim N.; Miller G.W.; Novel focused ultrasound gene therapy approach noninvasively restores dopaminergic neuron function in a rat Parkinson\u2019s disease model. Nano Lett 2017,17(6),3533-3542","journal-title":"Nano Lett"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666230330093829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215183\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666230330093829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T02:18:59Z","timestamp":1703211539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215183\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":180,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527322666230330093829","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}